期刊
EMERGING MICROBES & INFECTIONS
卷 9, 期 1, 页码 194-206出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2020.1713707
关键词
HIV-1; broadly neutralizing antibodies (bNAbs); efficacies; challenges; opportunities
资金
- National Natural Science Foundation of China [31670945]
- Yunan Province Major Project for Science and Technology of China [2018IA044]
- CAMS Innovation Fund for Medical Sciences [2017-12M-2-006, CAMS-I2M-1-014]
- PUMC Innovation Fund for postgraduates [2017-1002-1-18]
- National megaproject on key infectious diseases [2017ZX10202102-004-003]
Combination antiretroviral therapy (cART) is effective but not curative, and no successful vaccine is currently available for human immunodeficiency virus-1 (HIV-1). Broadly neutralizing antibodies (bNAbs) provide a new approach to HIV-1 prevention and treatment, and these promising candidates advancing into clinical trials have shown certain efficacies in infected individuals. In addition, bNAbs have the potential to kill HIV-1-infected cells and to affect the course of HIV-1 infection by directly engaging host immunity. Nonetheless, challenges accompany the use of bNAbs, including transient suppression of viraemia, frequent emergence of resistant viruses in rebound viraemia, suboptimal efficacy in virus cell-to-cell transmission, and unclear effects on the cell-associated HIV-1 reservoir. In this review, we discuss opportunities and potential strategies to address current challenges to promote the future use of immunotherapy regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据